Effect of imipramine on ether à‐go‐go potassium channel (Kv1.10) expression in DU145 prostate cancer cells. (3rd November 2021)

• Record Type: Journal Article
• Authors: Söğüt, Fatma; Çömelekoğlu, Ülkü; Dervişoğlu, Hülya; Eroğlu, Pelin; Yalin, Serap; Yilmaz, Necat Şakir
• Is Part Of: Andrologia. Volume 54:Number 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-11-03
• Subjects: DU145 cells -- Eag1 channels -- imipramine -- patch clamp -- prostate cancer; Andrology -- Periodicals; Infertility, Male -- Periodicals; 616.69
• DOI: 10.1111/and.14291
• Languages: English
• ISSNs: 0303-4569

Abstract

Abstract: In recent studies, it has been reported that ion channels play an important role in cancer formation. Therefore, it is possible that the use of pharmacological agents targeting ion channels will allow the development of new strategies for cancer treatment. In this study, we investigate the effect of imipramine on Eag1 channel expression in DU145 prostate cancer cells. Culture cells were divided into 4 groups as the control, 10, 50 and 75 µM imipramine. Eag1 channel currents and conductivity were determined by whole‐cell patch‐clamp technique and gene expression by real time‐polymerase chain reaction (RT‐PCR). Current records were taken before (at 0th minute, as control) and 10 min after imipramine administration to the cells. It was observed that all three doses of imipramine significantly reduced Eag1 currents and conductivity compared with the control. However, the differences between dose groups were not significant. Similarly, Eag1 channel protein expression was found to be significantly reduced for all three doses of imipramine compared with the control group, but there was no significant difference in gene expression between dose groups. Obtained results suggested that imipramine has the potential to be used as a pharmacological agent targeting the Eag1 channel in the treatment of prostate cancer.